New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Key Highlights
- ➤Week 112: ≥72% achieved PASI 90 and ≥70% achieved clear or almost clear skin
- ➤Week 64-112: ≥44% achieved complete skin clearance, measured by PASI 100
- ➤Week 64-112: 78% sustained clinically meaningful improvement in itch
- ➤85% of withdrawn PASI 90 responders regained response within 24 weeks of retreatment
- ➤Week 112 safety remained consistent, with no new safety signals identified
Expert Statements
Mark Lebwohl, M.D., Professor and Chair Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and ICONIC-LEAD study investigator
“As plaque psoriasis is a chronic lifelong disease, durable results are essential in therapy selection. With two-year data that show long-term skin clearance and a consistent safety profile, ICOTYDE is transforming how we think about plaque psoriasis treatment”
Mark Lebwohl, M.D., Professor and Chair Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai, and ICONIC-LEAD study investigator
“I'm excited to have this practice-changing targeted oral peptide as a first-line systemic therapy for both my adult and adolescent patients.”
David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson
“These long-term results affirm that ICOTYDE, as the first and only targeted oral peptide, represents a groundbreaking shift in the treatment of plaque psoriasis”
David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson
“Due to the chronic nature of the disease, long-term management is key, and ICOTYDE is delivering on the promise of transformational innovation to meet the needs of patients.”
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis PR Newswire
* Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile SPRING HOUSE, Pa., Oct. 9, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEAD(a) study evaluating ICOTYDE(®) (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor(1), in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis.
Get started
Create a free account to read the full story.